Newly Published Economic Analysis Finds NxThera's Minimally Invasive Rez?m® System Provides Cost-Effective Solution to Treat BPH

MAPLE GROVE, Minn., Jan. 18, 2018 /PRNewswire/ -- NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) technology to treat endourological conditions, today announced publication of a recent economic analysis which demonstrates its minimally invasive Rezu?m System to be a cost-effective and durable solution in treating benign prostatic hyperplasia (BPH). The findings, presented in a manuscript entitled "Cost-Effectiveness Analysis of Six Therapies for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia," were recently published in ClinicoEconomics and Outcomes Research.

The economic analysis compared six BPH therapies: combination drug therapy, Rez?m, Prostiva, UroLift, GreenLight and TURP. Findings showed combination drug therapies to be the least effective, with branded drugs as the most expensive treatment option ($7,082) overall. GreenLight and TURP procedures showed slightly more symptom relief compared to Rezu?m, but both cost nearly twice as much ($5,099 for GreenLight and $5,191 for TURP). While UroLift is similar in effectiveness, the cost ($6,386) is more than twice the amount of a Rezu?m procedure ($2,582).

"Evidence-based evaluations support Rezu?m as a clinically and cost-effective treatment for BPH," said Dr. James C. Ulchaker, lead author and urologist with the Cleveland Clinic in Cleveland, Ohio. "Using a robust economic model, compared with the other BPH treatment options at two years included in the analysis, the clinical improvements, with low retreatment rates and side effects, resulted in Rez?m being a much less expensive option in a urologist's BPH treatment armamentarium, and may be a sensible choice in a health care system seeking to contain costs."

"The findings from this economic analysis are important because BPH is among the top 10 most prominent and costly diseases in men over 50 years of age in the U.S. estimated at $4 billion annually, and the population of men 65 years and older is estimated to rise over the next 10 years, meaning the demand, and therefore the spending, for BPH treatments will continue to increase sharply," said Bob Paulson, president and CEO of NxThera. "Furthermore, studies have documented that 60 percent of men discontinue use of drug therapy to treat BPH after one year as a result of side effects, including sexual dysfunction, and lower degrees of symptom relief and quality of life. Rez?m offers a cost-effective BPH treatment option, providing durable and compelling symptom relief, without sexual dysfunction, which allow men to resume their quality of life, balanced with an efficient use of health care spending."

Rez?m uses the natural thermal energy stored in water vapor, or steam, to treat the enlarged and obstructive prostate tissue that causes BPH symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate. The water vapor is delivered into the targeted prostate tissue and when the vapor contacts the tissue it condenses, releasing the stored thermal energy, causing the obstructive prostate tissue cells to die. In the weeks following a Rez?m procedure, the body's natural healing response eliminates the treated tissue, shrinking the prostate. As the extra tissue is removed, the urethra opens back up, reducing BPH symptoms and improving the patient's quality of life. Studies have shown that the Rez?m treatment provides durable symptom relief and allows men to retain sexual function unlike surgical BPH treatments, which typically have higher incidences of long-term sexual side effects. To date, more than 17,000 men have been effectively treated with the Rez?m System across the U.S. and Europe.

For more information about the Rez?m System, visit www.rezum.com.

About NxThera and the Rez?m System
NxThera pioneered its Convective Water Vapor Energy (WAVE®) platform technology to treat a variety of endourological conditions, beginning with BPH. The company is conducting advanced development and clinical research to potentially expand application of its technology to include the targeted treatment of cancerous prostate, kidney and bladder tissue as well as OAB. NxThera's FDA-cleared Rez?m System is indicated to treat symptoms of BPH using thermal energy that is convectively delivered to obstructive prostate tissue in targeted, precise treatments, with minimal discomfort. Three-year clinical data demonstrates sustained improvements in LUTS, urine flow, quality of life, and preservation of sexual function. Founded in 2008, NxThera is located in Maple Grove, Minn. For more information, visit www.rezum.com.

SOURCE NxThera, Inc.